A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

Abstract Background In vitro drug screening studies have indicated that camostat mesilate (FOY-305) may prevent SARS-CoV-2 infection into human airway epithelial cells. This study was conducted to investigate whether camostat mesilate is an effective treatment for SARS-CoV-2 infection (COVID-19). Me...

Full description

Bibliographic Details
Main Authors: Taku Kinoshita, Masahiro Shinoda, Yasuhiro Nishizaki, Katsuya Shiraki, Yuji Hirai, Yoshiko Kichikawa, Kenji Tsushima, Masaharu Sinkai, Naoyuki Komura, Kazuo Yoshida, Yasutoshi Kido, Hiroshi Kakeya, Naoto Uemura, Junichi Kadota
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Medicine
Subjects:
Camostat mesilate
COVID-19
Randomized controlled trial
SARS-CoV-2
Online Access:https://doi.org/10.1186/s12916-022-02518-7

Internet

https://doi.org/10.1186/s12916-022-02518-7

Similar Items